Methods of treating tumors with anti-TIGIT antibodies
The present disclosure relates to methods of treating or the manufacture of a medicament for treating cancer by using pharmaceutical formulations or medicaments comprising anti-TIGIT monoclonal antibodies that are suitable for co-administration or co-formulation with anti-PD-L1 monoclonal antibodies...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
16.12.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates to methods of treating or the manufacture of a medicament for treating cancer by using pharmaceutical formulations or medicaments comprising anti-TIGIT monoclonal antibodies that are suitable for co-administration or co-formulation with anti-PD-L1 monoclonal antibodies. The present disclosure also relates to articles of manufacture comprising single doses of anti-TIGIT monoclonal antibodies or both anti-TIGIT and anti-PD-L1 monoclonal antibodies and methods of treating cancer using such articles of manufacture and the formulations contained therein. |
---|---|
Bibliography: | Application Number: TW20240112381 |